Shakespeare once asked, “What’s in a name? Would a rose by any other name smell as sweet?” And in the case of Denali, would a mountain by another name be as magnificent?
There is Mount Foraker, which was originally Sultana, Denali’s woman, or wife. And there is Mount Hunter, which was Begguya, their child. Like Denali, Mount Foraker — Alaska’s second-tallest ...
After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...
A Denali Therapeutics drug for the rare enzyme deficiency Hunter syndrome is still in pivotal testing, but the company has guidance from the FDA on a pathway to get this therapy to the market sooner.
Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24 ...
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter ...
Denali Therapeutics Inc. announced positive long-term data from its Phase 1/2 study of tividenofusp alfa (DNL310) in patients with Hunter syndrome (MPS II), showing sustained reductions in key ...
(RTTNews) - Denali Therapeutics (DNLI), a biopharmaceutical company, on Thursday presented the primary analysis of its Phase 1/2 study for tividenofusp alfa or DNL310 in Hunter syndrome or MPS II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback